Search - tctmd.com

Displaying 381 - 400 of 542

Sort: Relevancy | Date

News Daily News

Digital Tools Show Promise for Helping STEMI and NSTEMI Patients Avoid Readmission

L.A. McKeown

April 09, 2019

News Daily News

Disparities Seen in Uptake of DOACs for VTE

Todd Neale

April 05, 2019

News Daily News

Many Statin-Eligible Patients Don’t Take Meds, and Say Doctor Is to Blame

Michael O'Riordan

March 27, 2019

News Conference News ACC 2019

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Michael O'Riordan

March 17, 2019

News Conference News

Flu Vaccination Tied to Less MI in Hospitalized Patients

Todd Neale

March 13, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Conference News ISC 2019

Cilostazol-Based DAPT Safe, Effective in Patients at High Risk for Recurrent Stroke

Todd Neale

February 12, 2019

News Daily News

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Michael O'Riordan

January 29, 2019

News Daily News

Bias Over Knowledge: Whether Patients Get Guideline-Recommended Statins Depends on Physician Beliefs

Yael L. Maxwell

January 10, 2019

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

L.A. McKeown

December 18, 2018

News Daily News

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Shelley Wood

December 18, 2018

News Daily News

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Michael O'Riordan

December 03, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2018

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Yael L. Maxwell

November 16, 2018

News Opinion Conversations in Cardiology

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

Advertisement

Digital Tools Show Promise for Helping STEMI and NSTEMI Patients Avoid Readmission

Disparities Seen in Uptake of DOACs for VTE

Many Statin-Eligible Patients Don’t Take Meds, and Say Doctor Is to Blame

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Flu Vaccination Tied to Less MI in Hospitalized Patients

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Cilostazol-Based DAPT Safe, Effective in Patients at High Risk for Recurrent Stroke

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Bias Over Knowledge: Whether Patients Get Guideline-Recommended Statins Depends on Physician Beliefs

Top News in Endovascular Therapy: 2018

Top News in Prevention: 2018

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

TCTMD’s Top 10 Most Popular Stories for November 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content